Proactive Investors - Run By Investors For Investors
Why invest in IMM?
ImmuPharma PLC: DEEP DIVE
OVERVIEW

ImmuPharma continues to build data package for flagship lupus treatment

Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year
scientist in lab
OVERVIEW: IMM The Big Picture
Despite last year’s setback, ImmuPharma remains confident in “blockbuster potential” of Lupuzor
  • Flagship drug is Lupuzor – a treatment for lupus

  • Results from follow-up study due within next few months

  • Nucant cancer treatment also going through the clinic

  • Ureka subsidiary being divested

 

What it does

ImmuPharma PLC (LON:IMM) specialises in developing drugs for serious medical conditions for which there is a distinct lack of existing treatments.

Its flagship drug is called Lupuzor – a treatment for the autoimmune disease lupus.

The drug missed its primary endpoint in a phase II study last year, but the outcome was more nuanced than the top line results suggested and actually showed that Lupuzor worked well in certain patients, chiefly those who were antibody-positive.

The results certainly haven’t held back ImmuPharma or its top drug. In fact, boss Tim McCarthy has said that Lupuzor still possesses “blockbuster potential”, meaning it could rack more than US$1bn in annual sales.

After the end of the phase III trial, 62 patients took part in a ‘follow-up’ study – called an open-label extension study. Results from this are expected between April and June.

On top of that, another 500 lupus sufferers are being given access to Lupuzor for the next two years as part of a managed access programme.

In addition to helping patients, the AIM-quoted drug developer expects to collect more valuable data on Lupuzor, which will be useful if and when it decides to press ahead with regulatory filings.

Blue sky

In the immediate future, results from the Lupuzor follow-up study are due by the end of June, while the managed access programme is set to complete towards the end of 2020.

Should Lupuzor prove itself in those two tests, ImmuPharma will use the data to try to get full regulatory approval the drug, something bosses hope to achieve “in the medium term”.

Lupuzor isn’t ImmuPharma’s only drug going through the clinic. Its Nucant cancer treatment has yielded “promising results” in two phase I safety and dose-finding studies.

The company has signed heads of terms on a clinical development collaboration with oncology specialist Incanthera, in which ImmuPharma has taken a £2mln stake.

A licence agreement between the two is expected to be signed by the end of March, a deal which is likely to see Incanthera pay an upfront licence fee of £1mln in shares and cover all the development costs for the Nucant programme.

All future commercialisation revenues will be shared equally, ImmuPharma has said.

What the boss is saying

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
cannabis
February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
1550850611_CancerHeadline.jpg
February 22 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use